SCHEMBL1707866

SCHEMBL1707866

COc1cc(N)c(Cl)cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.78
GAA P10253 3/20 0.58
KDM4E B2RXH2 1/20 0.45
TUBB4A P04350 1/20 0.44
TUBB P07437 1/20 0.44
TUBA3C P0DPH7 1/20 0.44
TUBA1B P68363 1/20 0.44
TUBA4A P68366 1/20 0.44
TUBB4B P68371 1/20 0.44
TUBB3 Q13509 1/20 0.44
TUBB2A Q13885 1/20 0.44
TUBB8 Q3ZCM7 1/20 0.44
TUBA3E Q6PEY2 1/20 0.44
TUBA1A Q71U36 1/20 0.44
TUBA1C Q9BQE3 1/20 0.44
TUBB6 Q9BUF5 1/20 0.44
TUBB2B Q9BVA1 1/20 0.44
TUBB1 Q9H4B7 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
CYP3A4 P08684 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4805724 0.88 GAA (0.75) NPC1GAATUBB4ATUBBTUBA3C
SCHEMBL108063 0.88 NPC1 (1.00) NPC1GAATUBB4ATUBBTUBA3C
SCHEMBL29601238 0.88 NPC1 (1.00) NPC1GAATUBB4ATUBBTUBA3C
SCHEMBL9116148 0.88 NPC1 (0.83) NPC1GAAKDM4ETUBB4ATUBB
Hydrochloric Acid SCHEMBL3276689 0.86 NPC1 (0.95) NPC1GAATUBB4ATUBBTUBA3C
SCHEMBL11757764 0.86 NPC1 (0.72) NPC1GAATUBB4ATUBBTUBA3C
SCHEMBL4388470 0.84 NPC1 (0.63) NPC1GAAKDM4ETUBB4ATUBB
SCHEMBL5257080 0.84 NPC1 (0.69) NPC1GAATUBB4ATUBBTUBA3C
SCHEMBL29466462 0.83 GAA (0.83) NPC1GAATAAR1CYP3A4ALDH1A1
SCHEMBL92067 0.83 GAA (0.83) NPC1GAATAAR1CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100475-A1 COMPOSITION FOR IMAGE RECORDING AND METHOD FOR PRODUCING SAME キヤノン株式会社 2025-05-15 WO disclosed
US-20220162172-A1 QUINAZOLINONE COMPOUNDS CEREPEUT, INC. 2022-05-26 US disclosed
US-10251827-B2 Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst L'OREAL (FR) 2019-04-09 US disclosed
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-05-31 US disclosed
EP-3292107-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES Bayer Pharma Aktiengesellschaft (DE) 2018-03-14 EP disclosed
WO-2016177658-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-11-10 WO disclosed
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2016-05-12 US disclosed
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2016-05-12 US disclosed
WO-2014202787-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST L'OREAL (FR) 2014-12-24 WO disclosed
CN-102892765-A Novel cyclohexylamine derivatives having beta 2 adrenergic agonist and M3 muscarinic antagonist activity ALMIRALL SA 2013-01-23 CN disclosed
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2012-06-07 US disclosed
EP-2440534-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2012-04-18 EP disclosed
WO-2010142766-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-16 WO disclosed
EP-0122533-B1 COLOUR-PHOTOGRAPHIC RECORDING MATERIAL CONTAINING A COLOUR COUPLER Agfa-Gevaert AG (DE) 1989-01-25 EP disclosed
US-4529691-A Non-diffusible yellow coupler AGFA-GEVAERT AG (DE) 1985-07-16 US disclosed
EP-0122533-A2 Colour-photographic recording material containing a colour coupler Agfa-Gevaert AG (DE) 1984-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS ZAP70, LCK, DPY30 NPC1 4384/4885GAA 2193/4885KDM4E 1349/4885
US-10251827-B2 Oxidation dyeing process using a composition comprising a monoaminobenzene and a metal catalyst KRT18, CYB5R3, CBR3 NPC1 4723/4885GAA 4479/4885KDM4E 1988/4885
US-20220162172-A1 QUINAZOLINONE COMPOUNDS NDUFAB1, NDUFV1, NDUFV2 NPC1 322/4885GAA 247/4885KDM4E 4109/4885
US-20180148418-A1 AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES C1R, C9, C1S NPC1 558/4885GAA 1029/4885KDM4E 2120/4885
US-20160128922-A1 OXIDATION DYEING PROCESS USING A COMPOSITION COMPRISING A MONOAMINOBENZENE AND A METAL CATALYST KRT18, CYB5R3, CBR3 NPC1 4723/4885GAA 4531/4885KDM4E 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.